SYNTHENTIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS
The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
1 . A method of reducing seizure frequency in a subject having epilepsy, the method comprising:
transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
2 . The method of claim 1 , wherein the seizure frequency is reduced by 30%.
3 . The method of claim 1 , wherein the seizure frequency is reduced by 50%.
4 . The method of claim 1 , wherein focal onset seizures in adults are reduced.
5 . The method of claim 1 , wherein focal aware seizures are reduced.
6 . The method of claim 1 , wherein focal impaired awareness seizures are reduced.
7 . The method of claim 1 , wherein focal compared awareness with generalized tonic-clonic seizures are reduced.
8 . The method of claim 1 , wherein the subject has a high seizure frequency.
9 . The method of claim 1 , wherein the epilepsy is drug resistant epilepsy.
10 . The method of claim 1 , administering at least one anti-epileptic drug selected from the group consisting of levetiracetam, carbamazepine, topiramate, lamotrigine, lacosamide, clonazepam, valproate, clobazam, phenytoin, eslicarbaazepine, and oxcarbazepine.
11 . The method of claim 1 , wherein the CBD is (−)-CBD.
12 . The method of claim 1 , wherein the effective amount of CBD is between about 195 mg and about 780 mg total daily.
13 . The method of claim 1 , wherein the effective amount of CBD is 195 mg in divided daily doses.
14 . The method of claim 1 , wherein the effective amount of CBD is 390 mg in divided daily doses.
15 . The method of claim 1 , wherein the effective amount of CBD is 585 mg in divided daily doses.
16 . The method of claim 1 , wherein the effective amount of CBD is 780 mg in divided daily doses.
17 . The method of claim 1 , wherein the effective amount of CBD is provided in a 97.5 mg single use sachet.
18 . The method of claim 1 , wherein the effective amount of CBD is provided in a 195 mg single use sachet.
19 . The method of claim 1 , wherein the effective amount of CBD is provided in a 390 mg single use sachet.
20 . The method of claim 1 , wherein the CBD is formulated as a gel.
21 . The method of claim 20 , wherein the CBD is formulated as a permeation enhanced gel.
22 . The method of claim 1 , wherein the CBD is administered in a single daily dose.
23 . The method of claim 1 , wherein the CBD is administered in two daily doses.
24 . The method of claim 1 , wherein the CBD is a synthetic CBD.
25 . The method of claim 1 , wherein the CBD is a pure CBD.
26 . The method of claim 1 , wherein transdermally administering an effective amount of CBD reduces an intensity of at least one adverse event relative to orally administering CBD.
27 . The method of claim 26 , wherein the at least one adverse event is selected from the group consisting of somnolence, psychoactive effects, liver function, and GI related adverse events.
28 . The method of claim 1 , wherein the subject is an adult.